HYUNDAI BIOLAND Co.,Ltd. (KOSDAQ:052260)
4,325.00
-80.00 (-1.82%)
At close: Oct 23, 2026
HYUNDAI BIOLAND Revenue
HYUNDAI BIOLAND had revenue of 40.27B KRW in the quarter ending June 30, 2026, with 16.35% growth. This brings the company's total for the last twelve months to 140.70B, up 11.51% year-over-year. In the year 2025, HYUNDAI BIOLAND had annual revenue of 130.51B with 9.19% growth. That makes HYUNDAI BIOLAND the 22,200th largest company in the world by revenue and 1,240th in South Korea.
Revenue (ttm)
140.70B
Revenue Growth
+11.51%
P/S Ratio
0.92
Revenue / Employee
416.27M
Employees
338
Market Cap
129.75B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full HYUNDAI BIOLAND breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 130.51B | 10.99B | 9.19% |
| Dec 31, 2024 | 119.52B | 22.80B | 23.57% |
| Dec 31, 2023 | 96.72B | -2.43B | -2.45% |
| Dec 31, 2022 | 99.15B | -3.65B | -3.55% |
| Dec 31, 2021 | 102.80B | 13.90B | 15.64% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| NOVAREX | 404.26B |
| Ahn-Gook Pharmaceutical | 345.08B |
| Cosmax Nbt | 335.18B |
| DongKoo Bio & Pharma | 241.43B |
| Kyung Dong Pharmaceutical | 201.12B |
| DAE HWA Pharmaceutical | 148.75B |
| OPTUS Pharmaceutical | 94.47B |
| High Tech Pharm | 69.41B |